GUT-108
/ Gusto Global
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 20, 2022
"Hopefully, this bodes well for Dr. Sartor's GUT-103 and GUT-108 therapies."
(@tpasinet)
June 09, 2021
Healthy Microbiome Designed by Gusto Global Shows Promise to Radically Change Treatment for Inflammatory Diseases
(Businesswire)
- "Gusto Global...has developed novel consortia of bacteria that shows promise as a 'breakthrough' therapy for treating Crohn’s disease and ulcerative colitis in patients. A new study published this month in Nature Communications by Gusto Global and top UNC-Chapel Hill scientists demonstrated that the live bacterial consortia, called GUT-103 and GUT-108, prevented and treated chronic immune-mediated colitis in humanized mouse models...GUT-108 is expected to advance into Phase 1 clinical trial."
Preclinical • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 2
Of
2
Go to page
1